Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RX-AF01
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
RX-AF01 is an investigational live biotherapeutic product consisting of the bacterial strain *Alisipes finegoldii*, a Gram-negative anaerobic bacterium naturally found in the human intestine. [3] Developed by a research group at Sun Yat-sen University, RX-AF01 is designed to function as an anti-tumor agent. [3, 4] Preclinical research suggests that it enhances the anti-tumor activity of PD-1 inhibitors by increasing the infiltration of CD4+ and CD8+ immune cells into the tumor microenvironment. [1, 3] It is currently being evaluated in a Phase 1 clinical trial in combination with the PD-1 antibody toripalimab for the treatment of various refractory advanced solid tumors. [3, 4]
- Other names
- Alisipes finegoldii
Beyond the preview
Go deeper on RX-AF01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RX-AF01.